Targeting CD56 (NCAM)-expressing neoplasms with lorvotuzumab mertansine

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 273-293

  Lambert, John M ^a   O'Leary, James ^a   Whiteman, Kathleen R ^a   Goldmacher, Victor S ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010267185     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_16     Document Type: Chapter

References (128)

1. Schubert J, Lanier LL, Schmidt RE (1989) Cluster report: CD56. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEG (eds) Leucocyte Typing IV: white cell differentiation antigens. Oxford University Press, New York, pp 699-702
2. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 236:799-806
3. Edelman GM, Crossin KL (1991) Cell adhesion molecules: Implications for a molecular histology. Annu Rev Biochem 60:155-190
4. Carbone DP, Koros AM, Linnoila RI, Jewett P, Gazdar AF (1991) Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. Cancer Res 51:6142-6149
5. Roy DC, Ouellet S, Le Houillier C, Ariniello PD, Perreault C, Lambert JM (1996) Elimination of neuroblastoma and small cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J Natl Cancer Inst 88:1136-1145
6. Roth J, Zuber C, Wagner P, Blaha I, Bitter-Suermann D, Heitz PU (1988) Presence of the long chain form of polysialic acid of the neural cell adhesion molecule in Wilms' tumor. Identification of a cell adhesion molecule as an oncodevelopmental antigen and implications for tumor histogenesis. Am J Pathol 133:227-240
7. Jin L, Hemperly JJ, Lloyd RV (1991) Expression of neural cell adhesion molecule in normal and neoplastic human neuroendocrine tissues. Am J Pathol 138:961-969
8. Prieto AL, Crossin KL, Cunningham BA, Edelman GM (1989) Localization of mRNA for neural cell adhesion molecule (N-CAM) polypeptides in neural and nonneural tissues by in situ hybridization. Proc Natl Acad Sci USA 86:9579-9583
9. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH (1991) Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 146:4421-4426
10. Griffin JD, Hercend T, Beveridge R, Schlossman SF (1983) Characterization of an antigen expressed by human natural killer cells. J Immunol 130:2947-2951
11. Ranheim TS, Edelman GM, Cunningham BA (1996) Homophilic adhesion mediated by the neural cell adhesion molecule involves multiple immunoglobulin domains. Proc Natl Acad Sci USA 93:4071-4075
12. Crossin KL, Krushel LA (2000) Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev Dyn 218:260-279
13. Atkins AR, Gallin WJ, Owens GC, Edelman GM, Cunningham BA (2004) Neural cell adhesion molecule (N-CAM) homophilic binding mediated by the two N-terminal Ig domains is influenced by intramolecular domain-domain interactions. J Biol Chem 279:49633-49643
14. Paratcha G, Ledda F, Ibanez CF (2003) The neural cell adhesion molecule NCAM is an alternative signaling receptor for GNDF family ligands. Cell 113:867-879
15. Walsh FS, Doherty P (1997) Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol 13:425-456
16. Saffell JL, Williams EJ, Mason IJ, Walsh FS, Doherty P (1997) Expression of a dominant negative FGF receptor inhibits axonal growth and FGF receptor phosphorylation stimulated by CAMs. Neuron 18:231-242, Erratum: Neuron 1998; 20:619
17. Francavilla C, Loeffler S, Piccini D, Kren A, Christofori G, Cavallaro U (2007) Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. J Cell Sci 120:4388-4394
18. Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D et al (2008) NCAM- induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J 27:2603-2615
19. Liu L, Haines S, Shew R, Akeson RA (1993) Axon growth is enhanced by NCAM lacking the VASE exon when expressed in either the growth substrate or the growing axon. J Neurosci Res 15:327-345
20. Chernyshova Y, Leshchyns'ka I, Hsu S-C, Schachner M, Sytnyk V (2011) The neural cell adhesion molecule promotes FGFR-dependent phosphorylation and membrane targeting of the exocyst complex to induce exocytosis in growth cones. J Neurosci 31:3522-3535
21. Pittet MJ, Speiser DE, Valmori D, Cerottini J-C, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148-1152
22. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E et al (2005) Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 102:2886-2891
23. brightCD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis. J Immunol 175:6133-6142
24. Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG (2006) Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Human Immunol 67:863-873
25. dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89-94
26. Lemster BH, Michel JJ, Montag DT, Paat JJ, Studenski SA, Newman AB, Vallejo AN (2008) Induction of CD56 and TCR-independent activation of T cells with aging. J Immunol 180:1979-1990
27. dim human NK cells. Blood 116:3689-3691
28. Johnson JP (1991) Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev 10:11-22
29. Gattenlohner S, Stuhmer T, Leich E, Reinhard M, Etschmann B, Volker HU et al (2009) Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development. Am J Pathol 174:1160-1171
30. Hemperly JJ, Edelman GM, Cunningham BA (1986) cDNA clones of the neural cell adhesion molecule (N-CAM) lacking a membrane-spanning region consistent with evidence for membrane attachment via a phosphatidylinositol intermediate. Proc Natl Acad Sci USA 83:9822-9826
31. Reyes AA, Small SJ, Akeson R (1991) At least 27 alternatively spliced forms of the neural cell adhesion molecule mRNA are expressed during rat heart development. Mol Cell Biol 11:1654-1661
32. Small SJ, Akeson R (1990) Expression of the unique NCAM VASE exon is independently regulated in distinct tissues during development. J Cell Biol 111:2089-2096
33. Dickson G, Gower HJ, Barton CH, Prentice HM, Elsom VL, Moore SE et al (1987) Human muscle neural cell adhesion molecule (N-CAM): identification of a muscle-specific sequence in the extracellular domain. Cell 50:1119-1130
34. Barton CH, Dickson G, Gower HJ, Rowett LH, Putt W, Elsom V et al (1988) Complete sequence and in vitro expression of a tissue-specific phosphatidylinositol-linked N-CAM isoform from skeletal muscle. Development 104:165-173
35. Gower HJ, Barton CH, Elsom VL, Thompson J, Moore SE, Dickson G, Walsh FS et al (1988) Alternative splicing generates a secreted form of N-CAM in muscle and brain. Cell 55:955-964
36. Murray BA, Owens GC, Prediger EA, Crossin KL, Cunningham BA, Edelman GM (1986) Cell surface modulation of the neural cell adhesion molecule resulting from alternative mRNA splicing in a tissue-specific developmental sequence. J Cell Biol 103:1431-1439
37. Liedtke S, Geyer H, Wuhrer M, Geyer R, Frank G, Gerardy-Schahn R et al (2001) Characterization on N-glycans from mouse brain neural cell adhesion molecule. Glycobiology 11:373-384
38. Ong E, Suzuki M, Belot F, Yeh J-C, Franceschini I, Angata K et al (2002) Biosynthesis of the HNK-1 glycans on O-linked oligosaccharides attached to the neural cell adhesion molecule (NCAM). J Biol Chem 277:18182-18190
39. Albach C, Damoc E, Denzinger T, Schachner M, Przybylski M, Schmitz B (2004) Identification of N-glycosylation sites of the murine neural cell adhesion molecule NCAM by MALDI-TOF and MALDI-FTICR mass spectrometry. Anal Bioanal Chem 378:1129-1135
40. Kleene R, Schachner M (2004) Glycans and neural cell interactions. Nat Rev Neurosci 5:195-08
41. Finne J, Finne U, Deagostini-Bazin H, Goridis C (1983) Occurrence of alpha 2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun 112:482-487
42. Foley DA, Swartzentruber KG, Lavie A, Colley KJ (2010) Structure and mutagenesis of neural cell adhesion molecule domains: evidence for flexibility in the placement of polysialic acid attachment sites. J Biol Chem 285:27360-27371
43. Hemperly JJ, Murray BA, Edelman GM, Cunningham BA (1986) Sequence of a cDNA clone encoding the polysialic acid-rich and cytoplasmic domains of the neural cell adhesion molecule N-CAM. Proc Natl Acad Sci USA 83:3037-3041
44. Roth J, Zuber C, Wagner P, Taatjes DJ, Weisgerber C, Heitz PU et al (1988) Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor. Proc Natl Acad Sci USA 85:2999-3003
45. Johnson CP, Fujimoto I, Rutishauser U, Leckband DE (2005) Direct evidence that neural cell adhesion molecule (NCAM) polysialylation increases intermembrane repulsion and abrogates adhesion. J Biol Chem 280:137-145
46. Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR et al (2004) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 64:4629-4636
47. Jensen M, Berthold F (2007) Targeting the neural cell adhesion molecule in cancer. Cancer Lett 258:9-21
48. Saito S, Tanio Y, Tachibana I, Hayashi S, Kishimoto T, Kawase I (1994) Complementary DNA sequence encoding the major neural cell adhesion molecule isoform in a human small cell lung cancer cell line. Lung Cancer 10:307-318
49. McNiff JM, Cowper SE, Lazova R, Subtil A, Glusac EJ (2005) CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both? J Cutan Pathol 32:541-545
50. Whiteman KR, Murphy MF, Cohane KP, Sun W, Carrigan CN, Mayo MF et al (2008) Preclinical evaluation of IMGN901 (huN901-DM1) as a potential therapeutic for ovarian cancer. Proc Am Assoc Cancer Res 49:Abstr 2135
51. Aletsee-Ufrecht M, Langley K, Rotsch M, Havemann K, Gratzl M (1990) NCAM: a surface marker for human small cell lung cancer cells. FEBS Lett 267:295-300
52. Rygaard K, Moller C, Bock E, Spang-Thomsen M (1992) Expression of cadherin and NCAM in human small cell lung cancer cell lines and xenografts. Br J Cancer 65:573-577
53. Kibbelaar RE, Moolenaar KE, Michalides RJ, Bitter-Suermann D, Addis BJ, Mooi WJ (1989) Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer. J Pathol 159:23-28
54. Zangemeister-Wittke U, Stahel RA (1999) Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci 55:1585-1598
55. Kontogianni K, Nicholson AG, Butcher D, Sheppard MN (2005) CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artifact. J Clin Pathol 58:978-980
56. Moolenaar CE, Pieneman C, Walsh FS, Mooi WJ, Michalides RJ (1992) Alternative splicing of neural-cell-adhesion molecule mRNA in human small-cell lung cancer cell line H69. Int J Cancer 51:238-243
57. Carrigan CN, Xu S, Zhao Y, Testa N, Gabriel R, O'Keefe J et al (2010) The antigen target of lorvotuzumab mertansine (IMGN901), CD56, is expressed at significant levels in Merkel cell carcinoma (MCC). Proc Am Assoc Cancer Res 51:Abstr 5335
58. Daniel L, Bouvier C, Chetaille B, Gouvernet J, Luccioni A, Rossi D et al (2003) Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol 34:528-532
59. Ikushima S, Yoshihara T, Matsumura T, Misawa S, Morioka Y, Hibi S, Imashuku S (1991) Expression of CD56/NCAM on hematopoietic malignant cells. A useful marker for acute monocytic and megakaryocytic leukemias. Int J Hematol 54:395-403
60. Baer MR, Stewart CC, Lawrence D, Authur DC, Byrd JC, Davey FR et al (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22; q22). Blood 90:1643-1648
61. Lanza F, Bi S, Castoldi G, Goldman JM (1993) Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 7:1570-1575
62. Feuillard J, Jacob M-C, Valensi F, Maynadie M, Gressin R, Chaperot L et al (2002) Clinical and biologic features of CD4+ CD56+ malignancies. Blood 99:1556-1563
63. van Camp B, Durie BGM, Spier C, de Waele M, Riet IV, Vela E et al (1990) Plasma cells in multiple myeloma express a natural killer associated antigen CD56 (NKH-1; Leu 10). Blood 76:377-382
64. Kaiser U, Auerbach B, Oldenburg M (1996) The neural cell adhesion molecule NCAM in multiple myeloma. Leuk Lymphoma 20:389-395
65. Amoureux M-C, Coulibaly B, Chinot O, Loundou A, Metellus P, Pougon G, Figarella-Branger D (2010) Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cells. BMC Cancer 10:91
66. Froesch BA, Stahel RA, Zangemeister-Wittke U (1996) Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells. Cancer Immunol Immunother 42:55-63
67. Blättler WA, Chari RVJ (2001) Drugs to enhance the therapeutic potency of anticancer antibodies: antibody-drug conjugates as tumor-activated prodrugs. In: Ojima I, Vite GD, Altmann K-H (eds) Anticancer agents: frontiers in cancer chemotherapy. ASC Symp Ser 796:317-338
68. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5:543-549
69. Myklebust AT, Godal A, Fodstad O (1994) Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Res 54:2146-2150
70. Zangemeister-Wittke U, Collinson AR, Frosch B, Waibel R, Schenker T, Stahel RA (1994) Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Br J Cancer 69:32-39
71. Yu A, Choi J, Ohno K, Levin B, Rom WN, Meruelo D (2000) Specific cell targeting for delivery of toxins into small-cell lung cancer using a streptavidin fusion protein complex. DNA Cell Biol 19:383-388
72. Robertus J (1991) The structure and action of ricin, a cytotoxic N-glycosidase. Semin Cell Biol 2:23-30
73. Krek CE, Ladino CA, Goldmacher VS, Blättler WA, Guild BC (1995) Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells. Protein Eng 8:481-489
74. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA (1991) An immuno- toxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 51:6236-6242
75. Fidias P, Grossbard M, Lynch TJ Jr (2002) A phase II study of the immunotoxin N901- blocked ricin in small-cell lung cancer. Clin Lung Cancer 3:219-222
76. Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blättler WA, Collinson AR et al (1997) Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 15:723-734
77. Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V et al (1994) Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl 8:57-59
78. Lynch TJ Jr (1993) Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest 103:436S-439S
79. Goldmacher VS, Lambert JM, Blättler WA (1992) The specific cytotoxicity of immunocon- jugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. Biochem Biophys Res Commun 183:758-766
80. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M (1997) Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res 3:339-345
81. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, Vitetta ES (2003) Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 21:387-391
82. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN et al (1993) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263-2271
83. Lambert JM (2010) Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer. Drugs Fut 35:471-480
84. Whiteman KR, Xie H, Mayo MF, Audette CA, Steeves RM, Glickman JN et al (2012) Lorvotuzumab mertansine, a CD56-targeting antibody-maytansinoid conjugate with potent antitumor activity against CD56-positive small cell lung cancer models. (submitted for publication)
85. Chari RVJ, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA et al (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 52:127-131
86. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM et al (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 91:969-973
87. Vater CA, Reid K, Bartle LM, Goldmacher VS (1995) Characterization of antibody binding to cell surface antigens using a plasma membrane-bound plate assay. Anal Biochem 224:39-50
88. Roguska MA, Pedersen JT, Henry AH, Searle SMJ, Roja CM, Avery B et al (1996) A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng 9:895-904, Erratum: Protein Eng. 1997; 10:181
89. Chari RVJ, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM et al (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immu- noconjugate formation. Cancer Res 55:4079-4084
90. Kupchan SM, Komoda Y, Court WA, Thomas GT, Smith RM, Karim A et al (1972) Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94:1354-1356
91. Remillard S, Rebhun LI, Howie GA, Kupchan SM (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002-1005
92. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
93. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG (1976) Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 72(1):47-54
94. Wolpert-DeFilippes MK, Bono VH Jr, Dion RL, Johns DG (1975) Initial studies on may- tansine-induced metaphase arrest in L1210 murine leukemia cells. Biochem Pharmacol 24:1735-1738
95. Rao PN, Freireich EJ, Smith ML, Loo TL (1979) Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. Cancer Res 39:3152-3155
96. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Jordan MA (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9:2689-2699
97. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M et al (2011) Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjugate Chem 22:717-727
98. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14:2436-2446
99. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L et al (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244
100. Chari RVJ, Xie H, Steeves RM, Lambert JM (2005) Additive and synergistic effects of combination treatment with huN901-DM1 (BB-10901) and chemotherapeutic agents in small cell lung cancer xenograft tumor models. Proceedings of AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, p. 70 (Abstr A58)
101. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H et al (2010) Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 9:2700-2713
102. Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255:232-240
103. Minana R, Duran JM, Tomas M, Renau-Piqueras J, Guerri C (2001) Neural cell adhesion molecule is endocytosed via a clathrin-dependent pathway. Eur J Neurosci 13:749-756
104. Diestel S, Schaefer D, Cremer H, Schmitz B (2007) NCAM is ubiquitylated, endocytosed and recycled in neurons. J Cell Sci 120:4035-4049
105. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K et al (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433
106. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD et al (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether linked antibody- maytansinoid conjugates. Bioconjug Chem 21:84-92
107. Erickson H, Wilhelm S, Widdison W, Leece B, Sun X, Kovtun Y et al (2008) Evaluation of the cytotoxic potencies of the major maytansinoid metabolites of antibody-maytansinoid conjugates formed in preclinical mouse models. Proc Am Assoc Cancer Res 49:Abstr 2150
108. Sun X, Clancy L, Ellis M, Whiteman KR, Pinkas J, Lazar A, Erickson HK (2011) Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models. Proceedings of AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Mol Cancer Ther 10(Suppl 11):Abstr B195
109. Maloney E, Fishkin N, Audette C, Clancy L, Sun X, Chari R, Singh R (2009) Designing potent antibody-maytansinoid conjugates (AMCs): the impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity. Proceedings of AACR-NCI- EORTC International Conference: Molecular Targets and Cancer Therapeutics. Mol Cancer Ther; 8(Suppl 12):Abstr B120
110. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R et al (2011) Design of antibody- maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22:728-735
111. Skaletskaya A, Setiady YY, Park PU, Lutz RJ (2011) Lorvotuzumab mertansine (IMGN901) immune effector activity and its effect on NK cells. Proc Am Assoc Cancer Res 52:Abstr 770
112. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R et al (2012) Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30(3):1121-1131
113. Houghton PJ, Maris JM, Keir ST, Gorlick R, Kolb EA, Kang M et al (2011) Pediatric preclinical testing program (PPTP) stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901). Proceedings of AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics. Mol Cancer Ther 10 (Suppl 11):Abstr C105
114. Ishitsuka K, Jimi S, Goldmacher VS, Ab O, Tamura K (2008) Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol 141:129-131
115. Whiteman KR, Ab O, Bartle LM, Foley K, Goldmacher VS, Lutz RJ (2008) Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. Proc Am Assoc Cancer Res 49:Abstr 2146
116. Whiteman KR, Johnson HA, Xu Shanqin, Pinkas J and Lutz RJ (2011) Lorvotuzumab mer- tansine (IMGN901) in combination with standard-of-care paclitaxel/carboplatin therapy is highly active in a preclinical xenograft model of ovarian cancer. Proc Am Assoc Cancer Res 52:Abstr 1781
117. Whiteman KR, Johnson H, Xu S, Moreland J, Vyas V, Bartle LM et al (2009) Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. Proc Am Assoc Cancer Res 50:Abstr 2799
118. Tolcher AW, Forouzesh B, McCreery H, Hammond L, Patnaik A, Lambert J et al (2002) A phase I and pharmacokinetic study of BB-10901, a maytansinoid immunoconjugate, in CD56 expressing tumors. Eur J Cancer 38(Suppl 7):S152-S153, Abstr 509
119. McCann J, Fossella FV, Villalona-Calero MA, Tolcher AW, Fidias P, Raju R et al (2007) Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. J Clin Oncol 25(18S):Abstr 18084
120. Fossella F, Woll PJ, Lorigan P, Tolcher A, O'Brien M, O'Keeffe J et al (2009) Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma. J Thorac Oncol [13th World Conference on Lung Cancer, 2009] 4(Suppl 9):Abstr 6327 (PD 4.3.5)
121. Woll PJ, O'Brien M, Fossella F, Shah M, Clinch Y, O'Keeffe J et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol 21(Suppl 8):Abstr 536P
122. Chanan-Khan A, Wolf J, Garcia J, Gharibo M, Jagannath S, Manfredi D et al (2010) Efficacy analysis from a phase I study of lorvotuzumab mertansine (IMGN901) used as monotherapy in patients with heavily pre-treated CD56-positive multiple myeloma. Blood 116:Abstr 1962
123. Lutz RJ, Whiteman KR (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. mAbs 1:548-551
124. Woll P, Fossella FV, O'Brien MO, Clinch Y, Donaldson K, O'Keeffe J et al (2008) Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumors. EORTC-NCI- AACR international conference: molecular targets and cancer therapeutics (Abstract 510)
125. Berdeja JG, Ailawadhi S, Weitman SD, Zildjian S, O'Leary JJ, O'Keeffe J et al (2011) Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refrac- tory multiple myeloma (MM). J Clin Oncol 29:(Suppl):Abstr 8013
126. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG (2005) Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23:2300-2309
127. Berdeja JG, Ailawadhi MD, Niesvizky R, Wolf JL, Zildjian SH, O'Leary J, Chanan-Khan A (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalido- mide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma-a preliminary safety and efficacy analysis of the combination. Blood 116:Abstr 1934
128. Van Duijnhoven HL, Helfrich W, de Leij L, Roebroek AJ, van de Ven WJ, Healey K et al (1992) Splicing of the VASE exon of neural cell adhesion molecule (NCAM) in human small-cell lung carcinoma (SCLC). Int J Cancer 50:118-123